Intercept Pharmaceuticals (ICPT) PT Lowered to $115 at RBC Capital

RBC Capital lowered its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $115.00 (from $116.00) while maintaining an Outperform rating.

Analyst Brian Abrahams notes Ocaliva PBC revenues slightly beat expectations, with strengthening U.S. and ex-U.S. uptake following the label update. He said this should set a solid foundation as investors continue to shift focus away from NT PBC performance and toward the 1H19 REGENERATE interim.

You May Also Be Interested In

• XPeng (H-Shares) (9868:HK) (XPEV) PT Lowered to HK$70 at Macquarie
• BJ's Wholesale (BJ) PT Raised to $115 at UBS as Business Model 'Remains Relevant'
• XPeng (H-Shares) (9868:HK) (XPEV) PT Lowered to HK$71 at Bernstein SocGen Group